A Case of Refractory Pediatric Crohn's Disease with a Successful Treatment by Infliximab Therapy / 대한소화기학회지
The Korean Journal of Gastroenterology
;
: 297-301, 2005.
Artículo
en Coreano
| WPRIM
| ID: wpr-108014
ABSTRACT
Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Infusiones Intravenosas
/
Fármacos Gastrointestinales
/
Resumen en Inglés
/
Esquema de Medicación
/
Enfermedad de Crohn
/
Anticuerpos Monoclonales
Límite:
Niño
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
The Korean Journal of Gastroenterology
Año:
2005
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS